Emerging Cancer Vaccines Market to 2017 - Novel, First-In-Class Vaccines in Phase II and Phase III Pipeline to Shape the Future Cancer Vaccines Market

Emerging Cancer Vaccines Market to 2017 - Novel, First-In-Class Vaccines in Phase II and Phase III Pipeline to Shape the Future Cancer Vaccines Market

Summary

GBI Research, the leading business intelligence provider, has released its latest research, “Emerging Cancer Vaccines Market to 2017 - Novel, First-In-Class Vaccines in Phase II and Phase III Pipeline to Shape the Future Cancer Vaccines Market”, which provides insights into the global emerging cancer vaccines market and a market forecast until 2017. The report provides an in-depth analysis of the five therapeutic indications for which vaccines are available in the market or which have a promising vaccine in Phase III of their pipeline. In addition, the report also includes various types of cancer vaccine development and vaccine delivery methods along with a case study, advantages and disadvantages for each type, insights into the cancer vaccines R&D pipeline, SWOT profiles of the vaccine companies, and major Mergers and Acquisitions (M&A), deals and co-developments.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

GBI Research’s analysis shows that the global cancer vaccines market for cervical cancer, prostate cancer, lung cancer, pancreatic cancer and melanoma was valued at $1,657m in 2010. The market is expected to witness a Compound Annual Growth Rate (CAGR) of 21% for the forecast period (2010-2017) and will reach $6.3 billion by 2017. The market will be driven by the launch of promising Phase III molecules in cervical cancer, lung cancer, pancreatic cancer and melanoma. With patent-protection granted to available vaccines, the market will demonstrate significant growth. Strategic consolidations through M&A, deals and co-developments will provide R&D, marketing, sales and regulatory support in the future and help gain a greater market share.

Scope

- The report provides a market characterization, pipeline analysis and key M&A trends in the cervical cancer, prostate cancer, lung cancer, pancreatic cancer and melanoma vaccines market.
- Descriptive case studies, advantages and disadvantages for various types of cancer vaccine development and vaccine delivery methods
- Data and analysis on the emerging cancer vaccines market
- Annualized market data for the cancer vaccines market, with forecasts to 2017
- Market data on the therapeutic landscape which covers cervical cancer, prostate cancer, lung cancer, pancreatic cancer and melanoma, including market size, market share and annual cost of vaccination
- Key drivers and restraints that have had a significant impact on the market and on each indication
- The competitive landscape of the emerging cancer vaccines market which includes companies such as Merck, Amgen, GlaxoSmithKline, Dendreon
- Key M&A, deals and co-developments that took place from 2004 to 2011 in the global cancer vaccines market

Reasons to buy

The report will enhance your decision-making capability. It will allow you to -
- Familiarize yourself with the different types of cancer vaccine development and vaccine delivery methods available, with case studies and analysis of advantages and disadvantages for a better understanding of the market.
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the potential region and therapeutic segments poised for strong growth.
- Devise a more tailored country strategy through the understanding of key drivers and barriers of each region’s cancer vaccines market.
- Develop key strategic initiatives by understanding the key focus areas and top selling vaccines of leading companies.
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships. SHOW LESS READ MORE >

1
1 3
1.1 List of Tables 6
1.2 List of Figures 8
2 Emerging Cancer Vaccines Market to 2017: Introduction 10
2.1 GBI Research Report Guidance 10
3 Emerging Cancer Vaccines Market to 2017: Cancer Vaccine Development 12
3.1 Different Approaches to Cancer Vaccine Development 12
3.1.1 Whole-Cell Cancer Vaccines 12
3.1.2 Antigen Vaccines 12
3.1.3 DNA Vaccines 13
3.1.4 Vector-based Vaccines 13
3.1.5 Dendritic Cell (DC) Vaccines 14
3.1.6 Idiotype Vaccines 14
3.2 Cancer Vaccines in Combination Therapy (Adjuvants) 15
3.2.1 Microbes 15
3.2.2 Substances Produced by Bacteria 15
3.2.3 Biological Products Derived from Non-Microbial Organisms 16
3.2.4 Non-Biological Substances 16
3.2.5 Natural or Synthetic Cytokines 17
4 Emerging Cancer Vaccines Market to 2017: Physical Delivery Methods 18
4.1 Introduction 18
4.1.1 Tattooing 18
4.1.2 Gene Gun 19
4.1.3 Ultrasound 19
4.1.4 Electroporation 20
4.1.5 Laser 20
5 Emerging Cancer Vaccines Market to 2017: Non-Physical Delivery Methods 21
5.1 Biological Gene Delivery Systems (Viral Vectors) 21
5.2 Non-Biological Gene Delivery Systems (Non-Viral Vectors) 21
5.2.1 Cationic Lipids/Liposomes 21
5.2.2 Polysaccharides and Cationic Polymers 22
5.2.3 Micro/Nano-particles 22
5.2.4 Cationic Peptides/CPP 23
5.2.5 Virus-Like Particles (VLPs) as an Efficient Delivery System 23
5.2.6 Delivery Systems in DC Vaccines 24
5.2.7 Delivery Systems in Protein/Peptide Vaccines 24
5.2.8 Mucosal Delivery System 24
6 Emerging Cancer Vaccines Market to 2017: Market Overview 25
6.1 Introduction 25
6.2 Revenue 25
6.3 Annual Cost of Vaccination 27
6.4 Target Population 28
6.4.1 Coverage Population 28
6.5 Unmet Needs 29
6.6 Drivers and Restraints 29
6.6.1 Drivers 29
6.6.2 Restraints 29
7 Emerging Cancer Vaccines Market to 2017: Therapeutic Landscape 31
7.1 Cervical Cancer Vaccines Market 31
7.1.1 Introduction 31
7.1.2 Unmet Needs 31
7.1.3 Revenue 32
7.1.4 Annual Cost of Vaccination 33
7.1.5 Target Population 34
7.1.6 Geographical Segmentation 36
7.1.7 Drivers and Restraints for the Cervical Cancer Vaccines Market 37
7.2 Prostate Cancer Vaccine Market 37
7.2.1 Introduction 37
7.2.2 Unmet Needs 37
7.2.3 Revenue 38
7.2.4 Annual Cost of Vaccination 39
7.2.5 Target Population 40
7.2.6 Geographical Segmentation 41
7.2.7 Drivers and Restraints for the Prostate Cancer Vaccines Market 42
7.3 Lung Cancer Vaccines Market 42
7.3.1 Introduction 42
7.3.2 Unmet Needs 42
7.3.3 Revenue 43
7.3.4 Annual Cost of Vaccination 44
7.3.5 Target Population 45
7.3.6 Geographical Segmentation 46
7.3.7 Drivers and Restraints for the Lung Cancer Vaccines Market 47
7.4 Pancreatic Cancer Vaccines Market 47
7.4.1 Introduction 47
7.4.2 Unmet Needs 47
7.4.3 Revenue 48
7.4.4 Annual Cost of Vaccination 49
7.4.5 Target Population 50
7.4.6 Geographical Segmentation 51
7.4.7 Drivers and Restraints for the Pancreatic Cancer Vaccines Market 52
7.5 Melanoma Vaccines Market 52
7.5.1 Introduction 52
7.5.2 Unmet Needs 52
7.5.3 Revenue 53
7.5.4 Annual Cost of Vaccination 54
7.5.5 Target Population 55
7.5.6 Geographical Segmentation 56
7.5.7 Drivers and Restraints for the Melanoma Vaccines Market 57
8 Emerging Cancer Vaccines Market to 2017: Geographical Landscape 58
8.1 The US 58
8.1.1 Revenue 58
8.1.2 Annual Cost of Vaccination 60
8.1.3 Target Population 61
8.2 Top Five Countries in Europe 63
8.2.1 Revenue 63
8.2.2 Annual Cost of Vaccination 64
8.2.3 Target Population 65
8.3 Japan 67
8.3.1 Revenue 67
8.3.2 Annual Cost of Vaccination 68
8.3.3 Target Population 69
9 Emerging Cancer Vaccines Market to 2017: Pipeline Analysis 70
9.1 Introduction 70
9.1.1 Research and Development Pipeline – Prostate Cancer Vaccines 72
9.1.2 Research and Development Pipeline – Lung Cancer Vaccines 78
9.1.3 Research and Development Pipeline – Pancreatic Cancer Vaccines 84
9.1.4 Research and Development Pipeline – Melanoma Vaccines 89
9.1.5 Research and Development Pipeline – Cervical Cancer Vaccines 102
9.2 R&D Trends 105
9.3 Profiles of Promising Drugs in the Emerging Cancer Vaccines Market to 2017 105
9.3.1 Stimuvax 105
9.3.2 OncoVEXGM-CSF 106
9.3.3 V503 106
9.3.4 GV1001 107
9.3.5 Lucanix 108
9.3.6 TG4010 108
10 Emerging Cancer Vaccines Market to 2017: Competitive Landscape 110
10.1 Marketed Cancer Vaccines 110
10.1.1 Gardasil 110
10.1.2 Cervarix 110
10.1.3 Provenge 111
10.2 Market Share Analysis 112
10.3 Competitive Profiling 113
10.3.1 Merck & Co., Inc. 113
10.3.2 Merck Serono 115
10.3.3 Amgen 116
10.3.4 GlaxoSmithKline 117
10.3.5 Dendreon 119
10.3.6 KAEL-Gemvax 120
11 Emerging Cancer Vaccines Market to 2017: Strategic Consolidations 121
11.1 Overview 121
11.1.1 M&A by Year 121
11.1.2 M&A by Geography 122
11.1.3 M&A by Value 123
11.1.4 M&A by Type 124
11.1.5 M&A by Company 125
11.1.6 Top 10 M&A 126
11.2 R&D Licensing Agreements 130
11.2.1 Deals by Year 130
11.2.2 Deals by Geography 131
11.2.3 Deals by Value 132
11.2.4 Deals by Company 133
11.2.5 Top 10 Deals 134
11.3 Co-Developments 139
11.3.1 Co-Developments by Year 139
11.3.2 Co-Developments by Geography 140
11.3.3 Co-Developments by Value 141
11.3.4 Top Five Co-Developments 142
12 Emerging Cancer Vaccines Market to 2017: Appendix 145
12.1 Market Definitions 145
12.2 Abbreviations 145
12.3 Research Methodology 147
12.3.1 Cancer Vaccine Development 147
12.3.2 Vaccine Delivery Methods 148
12.3.3 Market Overview 148
12.3.4 Therapeutic Landscape 149
12.3.5 Geographical Landscape 151
12.3.6 Pipeline Analysis 152
12.3.7 Competitive Landscape 152
12.3.8 Strategic Consolidations 153
12.4 Contact Us 153
12.5 Disclaimer 153
12.6 Sources 154

GBI Research, the leading business intelligence provider, has released its latest research, “Emerging Cancer Vaccines Market to 2017 - Novel, First-In-Class Vaccines in Phase II and Phase III Pipeline to Shape the Future Cancer Vaccines Market”, which provides insights into the global emerging cancer vaccines market and a market forecast until 2017. The report provides an in-depth analysis of the five therapeutic indications for which vaccines are available in the market or which have a promising vaccine in Phase III of their pipeline. In addition, the report also includes various types of cancer vaccine development and vaccine delivery methods along with a case study, advantages and disadvantages for each type, insights into the cancer vaccines R&D pipeline, SWOT profiles of the vaccine companies, and major Mergers and Acquisitions (M&A), deals and co-developments.

The Global Cancer Vaccines Market is Forecast to Grow at a CAGR of 21% between 2010 and 2017

Emerging Cancer Vaccines Market, Global, Revenue Forecasts ($m), 2006-2017

Source: GBI Research, Company Websites, Annual Reports, Press Releases, National Institutes of Health (NIH), National Cancer Institute (NCI), Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), World Health Organization (WHO), American Cancer Society, Globocan

The global cancer vaccines market is forecast to grow at a Compound Annual Growth Rate (CAGR) of 21% between 2010 and 2017, reaching revenues of $6.3 billion in 2017 from $1.7 billion in 2010.

The cancer vaccines market was occupied by three vaccines, namely, Gardasil from Merck, Cervarix from GlaxoSmithKline (GSK), and Provenge (sipuleucel-T) from Dendreon Corporation during the historical period 2006-2010. In the near future, cervical cancer, lung cancer, pancreatic cancer and melanoma are expected to witness the launch of cancer vaccines with better efficacy over the current treatment options.

Promising Vaccines to be Launched in Melanoma, Lung and Pancreatic Cancer will Face Less Competition due to Absence of Marketed Vaccines

The global cancer vaccines market is presently dominated by cervical and prostate cancer vaccines. Cervical cancer is the only cancer indication to have two vaccines already available in the market and a promising vaccine in Phase III. The global cancer vaccine pipeline has a high percentage of Phase II and Phase III vaccines. The promising cancer vaccines that are first-in-class and have a novel mechanism of action will face less competition due to absence of marketed vaccines in lung cancer, pancreatic cancer and melanoma. Until 2017, cervical cancer, pancreatic cancer and melanoma are expected to have one vaccine launch each. Moreover, the pre-clinical and Phase I stages of cancer vaccine pipeline development have low percentages of vaccines. This indicates that until 2017 the global cancer vaccines market, excluding cervical and lung cancer, is not expected to face much competition until a second launch is targeted in the same indication as that of the first.

Merck & Co., Inc.
Merck Serono
Amgen
GlaxoSmithKline
Dendreon
KAEL-Gemvax